Drugs / AGN-242428
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04030962 | Mar 2020 → Mar 2022 | dry eye syndrome | AbbVie | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03339999 | Nov 2017 → Mar 2018 | psoriasis | Vitae Pharmaceuticals, Inc. | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AGN-242428 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03339999 ↗ |
| Route | Oral | “oral capsule(s) once daily” NCT03339999 ↗ |